Cost-utility of ranibizumab versus aflibercept for treating Greek patients with visual impairment due to diabetic macular edema

Table 4 Base case results—ranibizumab PRN, and ranibizumab T&E vs aflibercept

	RAN PRN	RAN T&E	AFL	RAN PRN vs AFL	RAN T&E vs AFL
Costs	€12,180	€14,982	€15,004	−€2824	−€22
Years without visual impairment (BCVA >35 letters)	4.352	4.355	4.321	+0.031	+0.034
Total QALYs	8.59	8.59	8.54	+0.05	+0.05
Cost per year without visual impairment (BCVA >35 letters)	–	–	–	−€89,807	−€653
Cost per QALY	–	–	–	Dominant	Dominant
NMB				€3984	€1278

RAN PRN ranibizumab pro re nata; RAN T&E ranibizumab treat and extend; AFL aflibercept; BCVA best corrected visual acuity; QALY quality-adjusted life year; NMB net monetary benefit

ISSN: 1478-7547